Danaher Co. (NYSE:DHR) Shares Bought by Beaird Harris Wealth Management LLC

Beaird Harris Wealth Management LLC boosted its holdings in shares of Danaher Co. (NYSE:DHRFree Report) by 10.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 655 shares of the conglomerate’s stock after acquiring an additional 60 shares during the period. Beaird Harris Wealth Management LLC’s holdings in Danaher were worth $152,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cape Investment Advisory Inc. acquired a new position in Danaher during the fourth quarter worth about $25,000. BKM Wealth Management LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. purchased a new stake in Danaher in the fourth quarter valued at approximately $29,000. Rakuten Securities Inc. purchased a new stake in Danaher in the fourth quarter valued at approximately $36,000. Finally, Financial Connections Group Inc. purchased a new stake in Danaher in the fourth quarter valued at approximately $41,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 0.1 %

Shares of DHR stock traded down $0.16 during trading hours on Friday, hitting $254.85. 3,097,194 shares of the company were exchanged, compared to its average volume of 2,930,997. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. Danaher Co. has a one year low of $182.09 and a one year high of $269.11. The business’s 50-day simple moving average is $253.48 and its two-hundred day simple moving average is $244.30. The stock has a market capitalization of $188.76 billion, a price-to-earnings ratio of 43.19, a P/E/G ratio of 3.90 and a beta of 0.85.

Danaher (NYSE:DHRGet Free Report) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.36 earnings per share. Sell-side analysts predict that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Danaher news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 148,783 shares of company stock worth $37,536,717. Company insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

DHR has been the subject of several research reports. Bank of America boosted their price objective on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. TD Cowen boosted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird boosted their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, Jefferies Financial Group initiated coverage on shares of Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

Check Out Our Latest Analysis on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.